Home › Companies › Precision BioSciences, Inc. › 2025-2026
At Precision BioSciences, Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 60 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 226 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non-binding) basis, of the compensation of our named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Precision BioSciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 26, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Precision BioSciences, Inc.’s Form 8-K, filed May 26, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 21, 2026: 7 items on Precision BioSciences, Inc.’s Form 8-K, filed May 26, 2026: 1 approved · 6 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Precision BioSciences, Inc. in the interactive database Compare manager voting policies
These tallies are Precision BioSciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Melinda Brown | 14,348,888 | -- | -- | 4,978,645 | 2,977,334 | 74% | Not verified | — |
| Elect Director: Geno Germano | 14,288,270 | -- | -- | 5,039,263 | 2,977,334 | 74% | Not verified | — |
| 2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 22,198,597 | 99,879 | 6,391 | -- | 0 | 99.5% | Not verified | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 18,696,193 | 612,836 | 18,504 | -- | 2,977,334 | 97% | Not verified | — |
| 4. Approval of the amendment and restatement of the Company's 2019 Incentive Award Plan | 11,170,635 | 8,145,992 | 10,906 | -- | 2,977,334 | 58% | Not verified | — |
| 5. Approval of an amendment to the Company's Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation | 17,909,703 | 1,411,694 | 6,136 | -- | 2,977,334 | 93% | Not verified | — |
| 6. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals | 16,653,283 | 5,647,737 | 3,847 | -- | 0 | 75% | Approved | — |
Source: Precision BioSciences, Inc., Form 8-K, filed with the SEC on May 26, 2026 — read the filing on EDGAR.
Each item below shows how the 60 asset managers that disclosed a Precision BioSciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Geno Germano
Precision BioSciences, Inc.’s own tally for this item (“Elect Director: Geno Germano”): 14,288,270 for, 5,039,263 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,372,623 for, 10,157 withheld, 1,733 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 896,203 | 0 | 1,733 | 0 | For |
| Fidelity | 230,335 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 134,140 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 47,089 | 0 | 0 | 0 | For |
| BlackRock | 40,856 | 0 | 0 | 0 | For |
| Charles Schwab | 20,000 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 7,395 | Withhold |
| Equitable | 3,613 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 2,219 | Withhold |
| American Century | 0 | 0 | 0 | 534 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 387 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 9 | Withhold |
Combines 5 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Melinda Brown
Precision BioSciences, Inc.’s own tally for this item (“Elect Director: Melinda Brown”): 14,348,888 for, 4,978,645 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,380,018 for, 2,762 withheld, 1,733 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 896,203 | 0 | 1,733 | 0 | For |
| Fidelity | 230,335 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 134,140 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 47,089 | 0 | 0 | 0 | For |
| BlackRock | 40,856 | 0 | 0 | 0 | For |
| Charles Schwab | 20,000 | 0 | 0 | 0 | For |
| Northern Trust | 7,395 | 0 | 0 | 0 | For |
| Equitable | 3,613 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 2,219 | Withhold |
| American Century | 0 | 0 | 0 | 534 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 387 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 9 | Withhold |
93% Majority: yes · of votes cast
Description as filed by funds: Approval of an amendment to our Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation.
Precision BioSciences, Inc.’s own tally for this item (“5. Approval of an amendment to the Company's Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation”): 17,909,703 for, 1,411,694 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,202,476 for, 182,036 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 897,128 | 807 | 0 | 0 | For |
| Fidelity | 230,335 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 0 | 134,140 | 0 | 0 | Against |
| Jacob Funds Inc. | 0 | 47,089 | 0 | 0 | Against |
| BlackRock | 40,856 | 0 | 0 | 0 | For |
| Charles Schwab | 20,000 | 0 | 0 | 0 | For |
| Northern Trust | 7,395 | 0 | 0 | 0 | For |
| Equitable | 3,613 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,219 | 0 | 0 | 0 | For |
| American Century | 534 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 387 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
75% Approved · of votes cast
Description as filed by funds: Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals.
Precision BioSciences, Inc.’s own tally for this item (“6. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals”): 16,653,283 for, 5,647,737 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 6: Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,928 for, 1,381,584 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,928 | 895,007 | 0 | 0 | Against |
| Fidelity | 0 | 230,335 | 0 | 0 | Against |
| MERIDIAN FUND INC | 0 | 134,140 | 0 | 0 | Against |
| Jacob Funds Inc. | 0 | 47,089 | 0 | 0 | Against |
| BlackRock | 0 | 40,856 | 0 | 0 | Against |
| Charles Schwab | 0 | 20,000 | 0 | 0 | Against |
| Northern Trust | 0 | 7,395 | 0 | 0 | Against |
| Equitable | 0 | 3,613 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 2,219 | 0 | 0 | Against |
| American Century | 0 | 534 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 387 | 0 | 0 | Against |
| Guggenheim | 0 | 9 | 0 | 0 | Against |
58% Majority: yes · of votes cast
Description as filed by funds: Approval of the amendment and restatement of the Company's 2019 Incentive Award Plan.
Precision BioSciences, Inc.’s own tally for this item (“4. Approval of the amendment and restatement of the Company's 2019 Incentive Award Plan”): 11,170,635 for, 8,145,992 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 58% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 48,287 for, 1,336,226 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,198 | 896,738 | 0 | 0 | Against |
| Fidelity | 0 | 230,335 | 0 | 0 | Against |
| MERIDIAN FUND INC | 0 | 134,140 | 0 | 0 | Against |
| Jacob Funds Inc. | 47,089 | 0 | 0 | 0 | For |
| BlackRock | 0 | 40,856 | 0 | 0 | Against |
| Charles Schwab | 0 | 20,000 | 0 | 0 | Against |
| Northern Trust | 0 | 7,395 | 0 | 0 | Against |
| Equitable | 0 | 3,613 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 2,219 | 0 | 0 | Against |
| American Century | 0 | 534 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 387 | 0 | 0 | Against |
| Guggenheim | 0 | 9 | 0 | 0 | Against |
Combines 10 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers (commonly referred to as the "say-on-pay vote").
Precision BioSciences, Inc.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 18,696,193 for, 612,836 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 897,935 | 1 | 0 | 0 | For |
| Fidelity | 230,335 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 134,140 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 47,089 | 0 | 0 | 0 | For |
| BlackRock | 40,856 | 0 | 0 | 0 | For |
| Charles Schwab | 20,000 | 0 | 0 | 0 | For |
| Northern Trust | 7,395 | 0 | 0 | 0 | For |
| Equitable | 3,613 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,219 | 0 | 0 | 0 | For |
| American Century | 0 | 534 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 387 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 1,383,978 for, 535 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Octagon Capital Advisors LP | 2,236,732 | 0 | 0 | 0 | For |
| Aberdeen | 2,230,178 | 0 | 0 | 0 | For |
| Bleichroeder LP | 1,662,500 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 995,371 | 0 | 0 | 0 | For |
| Lynx1 Capital Management LP | 985,113 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 798,817 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 287,082 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 285,781 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 255,721 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 0 | 212,961 | 0 | 0 | Against |
| Vanguard | 174,775 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 134,140 | 0 | 0 | 0 | For |
| Two Sigma | 112,652 | 0 | 0 | 0 | For |
| BlackRock | 104,797 | 173 | 0 | 0 | For |
| State Street | 63,842 | 0 | 0 | 0 | For |
| Renaissance | 59,989 | 0 | 0 | 0 | For |
| Northern Trust | 40,943 | 0 | 0 | 0 | For |
| Velan Capital Investment Management LP | 40,000 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 21,977 | 0 | 0 | 0 | For |
| Charles Schwab | 20,000 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 17,285 | 0 | 0 | 0 | For |
| Citadel | 8,022 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 6,144 | 0 | 0 | Against |
| Vivo Capital, LLC | 4,675 | 0 | 0 | 0 | For |
| HAMILTON LANE ADVISORS LLC | 2,636 | 0 | 0 | 0 | For |
Institutional-manager reports, all 51 managers: 10,551,001 for, 219,812 against. Showing the 25 largest; every one is in the interactive database (link above).
99.5% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2026.
Precision BioSciences, Inc.’s own tally for this item (“2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 22,198,597 for, 99,879 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 1,384,513 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 897,936 | 0 | 0 | 0 | For |
| Fidelity | 230,335 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 134,140 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 47,089 | 0 | 0 | 0 | For |
| BlackRock | 40,856 | 0 | 0 | 0 | For |
| Charles Schwab | 20,000 | 0 | 0 | 0 | For |
| Northern Trust | 7,395 | 0 | 0 | 0 | For |
| Equitable | 3,613 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 2,219 | 0 | 0 | 0 | For |
| American Century | 534 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 387 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 25,802,247 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.48% |
| 2 | Fidelity | 0.89% |
| 3 | MERIDIAN FUND INC | 0.52% |
| 4 | Jacob Funds Inc. | 0.18% |
| 5 | BlackRock | 0.16% |
| 6 | Charles Schwab | 0.08% |
| 7 | Northern Trust | 0.03% |
| 8 | Equitable | 0.01% |
| 9 | Blackstone Alternative Investment Funds | <0.01% |
| 10 | American Century | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Octagon Capital Advisors LP | 8.67% |
| 2 | Aberdeen | 8.64% |
| 3 | Bleichroeder LP | 6.44% |
| 4 | DRIEHAUS CAPITAL MANAGEMENT LLC | 3.86% |
| 5 | Lynx1 Capital Management LP | 3.82% |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | 3.10% |
| 7 | MARSHALL WACE, LLP | 1.11% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.11% |
| 9 | Affinity Asset Advisors, LLC | 0.99% |
| 10 | Alyeska Investment Group, L.P. | 0.83% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Aberdeen Group plc | 8.29% | 13G |
| Bleichroeder Holdings | 7.36% | DEF14A |
| Bleichroeder LP | 7.36% | 13G |
| Octagon Capital Advisors LP | 6.40% | 13G |
| Lynx1 Capital Management LP | 5.39% | 13G |
| Empery Asset Management, LP | 5.09% | 13G |
| Weinstein Benjamin | 4.29% | 13G |
| Vanguard Group | 3.51% | 13F |
| Two Sigma | 1.19% | 13F |
| Geode Capital | 1.11% | 13F |
Percentages above are of 25,802,247 shares outstanding, as reported by Precision BioSciences, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Precision BioSciences, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Precision BioSciences, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Precision BioSciences (DTIL) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/precision-biosciences-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.